Botfet / Company detail

ANAB

rejected

AnaptysBio, Inc.

biotech

Moat scoreNot available: not scored quality failout of 100
Rejectionquality_fail

The numbers

Financial metrics

Quality gate and thesis context
Roic14.6%
Gross Margin99.0%
Revenue Cagr38.8%
Fcf Conversion-148.2%
Fcf Yield1.3%
Interest Coverage0.9x
Market Cap B$1.5B
PeNot available: not applicable loss making
Quality PassFail
Founder LedNo
Thesis AlignedYes
Moat QuantNot available: not scored quality fail

Why it may endure

Moat breakdown

Quant: Not available: not scored quality fail · Curator: Not available: not scored quality fail
Market Share StabilityNot available: not scored quality fail
Network EffectsNot available: not scored quality fail
Pricing PowerNot available: not scored quality fail
Regulatory MoatNot available: not scored quality fail
Switching CostsNot available: not scored quality fail
ConvictionNot available: not scored quality fail
LeadershipNot available: not scored quality fail
VisionNot available: not scored quality fail
← Back to the full screener